Epigenic Therapeutics is a pioneering biotechnology company focused on developing next-generation gene modulation therapies through the regulation of the epigenetic genome. Utilizing its proprietary EPIREG(TM) technology platform, Epigenic offers innovative therapeutic solutions that provide efficient, durable, and specific gene silencing without the safety concerns associated with traditional gene-editing tools. The company is advancing a diverse pipeline of product candidates targeting metabolic, cardiovascular, viral hepatitis, ocular, and autoimmune diseases, leveraging its EpiTax(TM) delivery platform and AIAID(TM) platform for precise epigenetic modulation.